Emergency Department and Research Unit UR06SP21, Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia.
Intensive Care Med. 2011 Feb;37(2):249-56. doi: 10.1007/s00134-010-2082-3. Epub 2010 Dec 7.
Noninvasive pressure support ventilation (NIPSV) and continuous positive airway pressure (CPAP) are both advocated in the treatment of cardiogenic pulmonary edema (CPE); however, the superiority of one technique over the other has not been clearly demonstrated. With regard to its physiological effects, we hypothesized that NIPSV would be better than CPAP in terms of clinical benefit.
In a prospective, randomized, controlled study performed in four emergency departments, 200 patients were assigned to CPAP (n = 101) or NIPSV (n = 99). Primary outcome was combined events of hospital death and tracheal intubation. Secondary outcomes included resolution time, myocardial infarction rate, and length of hospital stay. Separate analysis was performed in patients with hypercapnia and those with high B-type natriuretic peptide (>500 pg/ml).
Hospital death occurred in 5 (5.0%) patients receiving NIPSV and 3 (2.9%) patients receiving CPAP (p = 0.56). The need for intubation was observed in 6 (6%) patients in the NIPSV group and 4 (3.9%) patients in the CPAP group (p = 0.46). Combined events were similar in both groups. NIPSV was associated to a shorter resolution time compared to CPAP (159 ± 54 vs. 210 ± 73 min; p < 0.01), whereas the incidence of new myocardial infarction was not different between both groups. Similar results were found in hypercapnic patients and those with high B-type natriuretic peptide.
During CPE, NIPSV accelerates the improvement of respiratory failure compared to CPAP but does not affect primary clinical outcome either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide.
无创压力支持通气(NIPSV)和持续气道正压通气(CPAP)均被推荐用于治疗心源性肺水肿(CPE);然而,一种技术优于另一种技术的优势尚未得到明确证明。就其生理效应而言,我们假设 NIPSV 在临床获益方面优于 CPAP。
在四个急诊科进行的前瞻性、随机、对照研究中,200 名患者被分配到 CPAP(n = 101)或 NIPSV(n = 99)组。主要结局是医院死亡和气管插管的联合事件。次要结局包括缓解时间、心肌梗死发生率和住院时间。分别对伴有高碳酸血症和高 B 型利钠肽(>500pg/ml)的患者进行分析。
NIPSV 组有 5 例(5.0%)患者发生医院死亡,CPAP 组有 3 例(2.9%)患者发生医院死亡(p = 0.56)。NIPSV 组有 6 例(6%)患者需要插管,CPAP 组有 4 例(3.9%)患者需要插管(p = 0.46)。两组的联合事件相似。与 CPAP 相比,NIPSV 组的缓解时间更短(159 ± 54 与 210 ± 73 分钟;p < 0.01),但两组新发心肌梗死的发生率无差异。在伴有高碳酸血症的患者和伴有高 B 型利钠肽的患者中也发现了类似的结果。
在心源性肺水肿期间,与 CPAP 相比,NIPSV 可加速呼吸衰竭的改善,但无论是在总体人群中还是在伴有高碳酸血症或高 B 型利钠肽的患者亚组中,都不会影响主要临床结局。